{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:29Z","timestamp":1790191949671,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["10.003.602"],"award-info":[{"award-number":["10.003.602"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Ropeginterferon alfa-2b (Ropeg-IFNa) is increasingly used in myeloproliferative neoplasms (MPN), particularly polycythemia vera, but real-world data across subtypes are limited. We evaluated clinical and molecular responses to Ropeg-IFNa in routine practice. Methods: We retrospectively analyzed 20 JAK2V617F-positive MPN patients treated at a tertiary center. Baseline features, dosing, treatment line, hematologic responses, adverse events, and serial JAK2V617F variant allele frequency (VAF) were extracted from records. Results: Median age at initiation was 53 years; 55% were ELN high-risk. Ropeg-IFNa was started first-line or after peginterferon alfa-2a, hydroxyurea, or a tapered JAK2 inhibitor. Mean treatment duration was 14 \u00b1 11 months at 195 \u00b1 143 \u00b5g Q2W. Hematologic control increased from 45% at the start to 60% at the last follow-up. Among patients with serial molecular monitoring (n = 11), median JAK2V617F VAF declined from 21.2 to 12.7%. Ropeg-IFNa was generally well tolerated; adverse effects were mostly manageable, although 3\/20 (15%) discontinued due to side effects, including mood disturbances, while others continued with supportive care and dose adjustments. Conclusions: In this single-center cohort, Ropeg-IFNa was tolerable and associated with improved hematologic control and modest VAF reductions, supporting its use in multi-subtype MPN cohorts. These findings underscore the value of longitudinal driver-mutation monitoring during therapy.<\/jats:p>","DOI":"10.3390\/jcm15010128","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:22:14Z","timestamp":1766575334000},"page":"128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-\u03b12b in Patients with Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-5929","authenticated-orcid":false,"given":"Matthias","family":"Christen","sequence":"first","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenic","family":"Kaderli","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Ratknic","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n Dante","family":"de Angelis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2034-9793","authenticated-orcid":false,"given":"Philipp Stefan","family":"Aebi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-1935","authenticated-orcid":false,"given":"Naomi","family":"Porret","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Tchinda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-4798","authenticated-orcid":false,"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuddri","family":"Rim","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale Julia","family":"Tanner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-0982","authenticated-orcid":false,"given":"Sebastian","family":"Mathes","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-4863","authenticated-orcid":false,"given":"Anne","family":"Angelillo-Scherrer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4753","authenticated-orcid":false,"given":"Alicia","family":"Rov\u00f3","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-185X","authenticated-orcid":false,"given":"Sara C.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e123-33","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","article-title":"Genetics of Myeloproliferative Neoplasms","volume":"35","author":"Szybinski","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2014.1.348","article-title":"Management of MPN beyond JAK2","volume":"2014","author":"Harrison","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.leukres.2017.08.002","article-title":"Ruxolitinib for the management of myelofibrosis: Results of an international physician survey","volume":"61","author":"Ellis","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: Contemporary review and 2024 treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vachhani, P., Mascarenhas, J., Bose, P., Hobbs, G., Yacoub, A., Palmer, J.M., Gerds, A.T., Masarova, L., Kuykendall, A.T., and Rampal, R.K. (2024). Interferons in the treatment of myeloproliferative neoplasms. Ther. Adv. Hematol., 15.","DOI":"10.1177\/20406207241229588"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","article-title":"Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment","volume":"37","author":"Gisslinger","year":"2023","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e30559","DOI":"10.1002\/pbc.30559","article-title":"Position paper: The time for cooperative group study of ropeginterferon alfa-2b in young patients with myeloproliferative neoplasms is now","volume":"70","author":"Kucine","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","article-title":"Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms","volume":"120","author":"Huang","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_14","first-page":"100360","article-title":"Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)","volume":"19","author":"Okikiolu","year":"2023","journal-title":"Leuk. Res. Reports"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2478\/prilozi-2023-0047","article-title":"Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms\u2013 Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience","volume":"44","author":"Cvetanoski","year":"2023","journal-title":"PRILOZI"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00277-024-05809-6","article-title":"Real-life use of ropeg-interferon \u03b12b in polycythemia vera: Patient selection and clinical outcomes","volume":"103","author":"Palandri","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: A post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_19","unstructured":"Gill, H., Masarova, L., Xiao, Z., Zhang, L., Komatsu, N., Jin, J., Kirito, K., Ohishi, K., Shirane, S., and Tashi, T. (2025, January 14). Better Safety and Efficacy with Ropeginterferon Alfa-2b over Anagrelide as Second-Line Treatment of Essential Thrombocythemia in the Topline Results of the Randomized Phase 3 SURPASS-ET Trial. Proceedings of the EHA Abstract, Online."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/j.clml.2020.05.018","article-title":"Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis","volume":"20","author":"Bewersdorf","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00277-025-06331-z","article-title":"Navigating the peginterferon Alfa-2a shortage: Practical guidance on transitioning patients to ropeginterferon alfa-2b","volume":"104","author":"Mesa","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e70109","DOI":"10.1002\/prp2.70109","article-title":"Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera","volume":"13","author":"Qin","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","article-title":"Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera","volume":"8","author":"Skov","year":"2024","journal-title":"Blood Adv."},{"key":"ref_27","unstructured":"(2025, July 09). Compendium\u2014Fachinformation Besremi. Available online: https:\/\/compendium.ch\/product\/1450797-besremi-inj-los-250-mcg-0-5-ml\/mpro."},{"key":"ref_28","unstructured":"European Medicines Agency (2025, July 09). EMA\u2014Besremi: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/besremi-epar-product-information_en.pdf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:42:12Z","timestamp":1766576532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15010128"],"URL":"https:\/\/doi.org\/10.3390\/jcm15010128","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}